Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Corporate Update (September 2017)

15 slides from Marinus Pharmaceuticals's corporate update, Sep 11, 2017

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private

  2. Slide 2: Agenda

    Agenda Introduction Christopher M. Cashman, CEO Phase 2 clinical trial design & data Dr. Lorianne Masuoka, CMO Case summaries of patients w/ CDKL5 disorder Dr. Nicola Specchio, Principal Investigator, Ospedale Pediatrico Bambino Gesù, Rome Closing Remarks Christopher M. Cashman, CEO 2

  3. Slide 3: Marinus's Development of Ganaxolone

    Marinus’s Development of Ganaxolone 3 Clear efficacy signal in refractory, CDKL5 disorder Need for mechanistically novel, efficacious & safe treatment options Committed to improving lives of patients with refractory epilepsies and psychiatric disorders

  4. Slide 4: Ganaxolone in children with CDKL5 Disorder

    Ganaxolone in children with CDKL5 Disorder Dr. Lorianne Masuoka, CMO

  5. Slide 5: Ganaxolone Targets Synaptic and Extrasynaptic GABAA Receptors

    5 Ganaxolone (GNX) Targets Synaptic and Extrasynaptic GABAA Receptors GNX is a synthetic analog of allopregnanolone GNX is designed to modulate both synaptic and extrasynaptic GABAA receptors to calm over-excited neurons

  6. Slide 6: CDKL5 Disorder – Rare, serious epileptic condition

    CDKL5 Disorder – Rare, serious epileptic condition 6 Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, difficult-to-control seizures, & severe neuro-developmental impairment Most can’t walk, talk or care for themselves Suffer from sc

  7. Slide 7: Phase 2 Study in CDKL5 Disorder

    Phase 2 Study in CDKL5 Disorder Trial Design: 2 sites in US; 1 site in Italy Oral ganaxolone - up to 1,800 mg/day + existing treatment regimen 6 females, 1 male; ages 2-16 Enrollment criteria: Confirmed CDKL5 mutation, stable background treatment, >4 seizures per 28-day period in baseline Endpoints:

  8. Slide 8: CDKL5 Disorder - Phase 2 Efficacy Data

    CDKL5 Disorder - Phase 2 Efficacy Data (as of Sept 11, 2017) 8 One-Year Extension Enrollees N=3* Median Seizure reduction 70% Median increase in seizure-free days 75% ITT Analysis N=7 Median seizure reduction from baseline 43% Median increase in seizure-free days 78% *One high responder is still und

  9. Slide 9: CDKL5 Disorder - Phase 2 Safety Profile

    CDKL5 Disorder - Phase 2 Safety Profile (as of Sept 11, 2017) Generally safe and well-tolerated No serious adverse events No reports of somnolence or dizziness (the most frequently reported AE in prior studies) Two patients discontinued prior to completing the 26-week treatment due to lack of effica

  10. Slide 10: Case summaries

    Case summaries Dr. Nicola Specchio Principal Investigator, Ospedale Pediatrico Bambino Gesù in Rome

  11. Slide 11: 8-Year Old Female

    8-Year Old Female Pre-ganaxolone treatment Post-ganaxolone treatment % Change Seizures daily spasms and tonic spasms spasms almost disappeared; improvement in attention and interaction; child shows affection Seizure frequency (per 28 days) 155 23 85% decrease in seizures Seizure-free days 9 16 >50%

  12. Slide 12: 11-Year Old Female

    11-Year Old Female Pre-ganaxolone treatment Post-ganaxolone treatment % Change Seizures multiple absences and spasms per day; severe behavior disturbance; frequent respiratory infections reduction of seizure frequency and intensity; improved quality of life; relieved by burden of epilepsy Seizure fr

  13. Slide 13: Why Ganaxolone in CDKL5 Disorder?

    Why Ganaxolone in CDKL5 Disorder? 13 Remarkable response in efficacy, safety and behavior with ganaxolone in this extremely rare, refractory patient population that has little success in controlling their seizures with existing treatment regimens Magnitude of Effect The children with improved seizur

  14. Slide 14: Thank you

    Thank you Follow @MarinusPharma on Twitter!

  15. Slide 15: Marinus Pharmaceuticals

    M‘SARINUS Follow @MarinusPharma on Twitter! PHARMACEUTICALS

Marinus Pharmaceuticals — Corporate Update (September 2017) on 6ix